From Financial Modeling Prep: 2025-05-14 16:00:00

PTC Therapeutics, Inc. has a ROIC of 31.66% and a WACC of 10.03%, indicating efficient capital use. Amicus Therapeutics, Inc. stands out with the highest ROIC to WACC ratio, while Ultragenyx Pharmaceutical Inc. and Blueprint Medicines Corporation show negative ratios, raising concerns about their capital utilization. Investors may find these metrics helpful in evaluating potential investments.



Read more at Financial Modeling Prep:: PTC Therapeutics, Inc. (NASDAQ:PTCT) Financial Ana…